$PALI
PALISADE BIO, INC.

2024 Q2 Form 10-Q Financial Statement

#000095017024058644 Filed on May 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $0.00 $0.00 $250.0K
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.583M $1.459M $1.538M
YoY Change 10.54% -5.14% -47.49%
% of Gross Profit
Research & Development $2.628M $2.214M $1.241M
YoY Change 20.72% 78.4% 29.41%
% of Gross Profit
Depreciation & Amortization $1.000K $1.000K $1.000K
YoY Change -50.0% 0.0% 0.0%
% of Gross Profit
Operating Expenses $4.211M $3.673M $2.779M
YoY Change 16.68% 32.17% -28.52%
Operating Profit -$4.211M -$3.673M -$2.529M
YoY Change 16.68% 45.24% -34.95%
Interest Expense $2.000K $1.000K $0.00
YoY Change -33.33% -100.0%
% of Operating Profit
Other Income/Expense, Net $131.0K $146.0K $189.0K
YoY Change -39.35% -22.75% -159.62%
Pretax Income -$4.080M -$3.527M -$2.340M
YoY Change 20.25% 50.73% -44.35%
Income Tax
% Of Pretax Income
Net Earnings -$4.080M -$3.527M -$2.340M
YoY Change 20.25% 50.73% -44.35%
Net Earnings / Revenue -936.0%
Basic Earnings Per Share -$3.32 -$4.59 -$0.54
Diluted Earnings Per Share -$3.32 -$4.59 -$0.54
COMMON SHARES
Basic Shares Outstanding 937.6K 12.77M 4.504M
Diluted Shares Outstanding 1.228M 768.1K 4.316M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.35M $11.28M $13.30M
YoY Change -30.79% -15.2% 100.14%
Cash & Equivalents $11.40M $11.30M $13.30M
Short-Term Investments
Other Short-Term Assets $831.0K $584.0K $684.0K
YoY Change -14.59% -14.62% -55.24%
Inventory
Prepaid Expenses
Receivables $300.0K
Other Receivables $78.00K
Total Short-Term Assets $12.31M $12.01M $14.31M
YoY Change -29.29% -16.05% 73.27%
LONG-TERM ASSETS
Property, Plant & Equipment $4.000K $5.000K $9.000K
YoY Change -63.64% -44.44% 350.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $387.0K $438.0K $643.0K
YoY Change -34.63% -31.88% 2373.08%
Total Long-Term Assets $559.0K $639.0K $953.0K
YoY Change -36.41% -32.95% 935.87%
TOTAL ASSETS
Total Short-Term Assets $12.31M $12.01M $14.31M
Total Long-Term Assets $559.0K $639.0K $953.0K
Total Assets $12.87M $12.65M $15.26M
YoY Change -29.63% -17.1% 82.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $514.0K $459.0K $706.0K
YoY Change -44.25% -34.99% -38.45%
Accrued Expenses $1.555M $1.670M $309.0K
YoY Change 160.03% 440.45% -46.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $349.0K $0.00 $0.00
YoY Change -15.09%
Total Short-Term Liabilities $2.836M $2.467M $1.315M
YoY Change 21.46% 87.6% -29.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $86.00K $121.0K $200.0K
YoY Change -44.52% -39.5% -88.19%
Total Long-Term Liabilities $86.00K $121.0K $200.0K
YoY Change -44.52% -39.5% -88.19%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.836M $2.467M $1.315M
Total Long-Term Liabilities $86.00K $121.0K $200.0K
Total Liabilities $2.922M $2.588M $1.515M
YoY Change 17.35% 70.83% -57.42%
SHAREHOLDERS EQUITY
Retained Earnings -$129.1M -$125.0M $111.5M
YoY Change -212.36% -212.11% 12.85%
Common Stock $9.000K $8.000K $46.00K
YoY Change -86.96% -82.61% -74.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.949M $10.06M $13.75M
YoY Change
Total Liabilities & Shareholders Equity $12.87M $12.65M $15.26M
YoY Change -29.63% -17.1% 82.78%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$4.080M -$3.527M -$2.340M
YoY Change 20.25% 50.73% -44.35%
Depreciation, Depletion And Amortization $1.000K $1.000K $1.000K
YoY Change -50.0% 0.0% 0.0%
Cash From Operating Activities -$3.499M -$3.180M -$3.526M
YoY Change 59.12% -9.81% -6.32%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.576M 2.024M 4.440M
YoY Change -32.64% -54.41% -5203.45%
NET CHANGE
Cash From Operating Activities -3.499M -3.180M -3.526M
Cash From Investing Activities 0.000
Cash From Financing Activities 3.576M 2.024M 4.440M
Net Change In Cash 77.00K -1.156M 914.0K
YoY Change -97.52% -226.48% -123.73%
FREE CASH FLOW
Cash From Operating Activities -$3.499M -$3.180M -$3.526M
Capital Expenditures $0.00
Free Cash Flow -$3.499M
YoY Change 58.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001357459
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-33672
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
PALISADE BIO, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2007292
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
7750 El Camino Real, Suite 2A
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92009
CY2024Q1 dei City Area Code
CityAreaCode
858
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
704-4900
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2024Q1 dei Trading Symbol
TradingSymbol
PALI
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
937562
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11276000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12432000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
737000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
896000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
12013000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
13328000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
170000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
198000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
438000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
490000
CY2024Q1 us-gaap Assets
Assets
12652000
CY2023Q4 us-gaap Assets
Assets
14052000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
459000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
698000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1670000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
831000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
213000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
778000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
125000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
121000
CY2024Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
0
CY2023Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
158000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2467000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2586000
CY2024Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2000
CY2024Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
61000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
61000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
90000
CY2024Q1 us-gaap Liabilities
Liabilities
2588000
CY2023Q4 us-gaap Liabilities
Liabilities
2739000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
851302
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
851302
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
618056
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
618056
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
135087000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
132811000
CY2024Q1 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-125033000
CY2023Q4 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-121506000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
10064000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11313000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12652000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14052000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
250000
CY2024Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2214000
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1241000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1459000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-278000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
615000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1538000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
3673000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2779000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3673000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2529000
CY2024Q1 us-gaap Interest Expense
InterestExpense
1000
CY2023Q1 us-gaap Interest Expense
InterestExpense
0
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
147000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
189000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
146000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
189000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3527000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2340000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
768137
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
768137
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
287702
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
287702
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.59
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.59
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.13
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.13
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
11313000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3527000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
118000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
10064000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12479000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2340000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
93000
CY2023Q1 pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
1349000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
13747000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3527000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2340000
CY2024Q1 us-gaap Depreciation
Depreciation
1000
CY2023Q1 us-gaap Depreciation
Depreciation
1000
CY2024Q1 pali Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
28000
CY2023Q1 pali Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
25000
CY2024Q1 pali Recurring Fair Value Measurements Of Liabilities
RecurringFairValueMeasurementsOfLiabilities
0
CY2023Q1 pali Recurring Fair Value Measurements Of Liabilities
RecurringFairValueMeasurementsOfLiabilities
43000
CY2024Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-4000
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
118000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
93000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
250000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-174000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-970000
CY2024Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-565000
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-295000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-28000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-25000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3180000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3526000
CY2024Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
158000
CY2023Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
88000
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2231000
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2503000
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2710000
CY2024Q1 pali Payment Of Warrant Inducement Issuance Costs
PaymentOfWarrantInducementIssuanceCosts
321000
CY2023Q1 pali Payment Of Warrant Inducement Issuance Costs
PaymentOfWarrantInducementIssuanceCosts
0
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
413000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2024000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4440000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1156000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
914000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12458000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12409000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11302000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13323000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11276000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13297000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11302000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13323000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
2000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2024Q1 pali Warrant Inducement And Equity Issuance Costs Included In Accounts Payable And Accrued Liabilities
WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
22000
CY2023Q1 pali Warrant Inducement And Equity Issuance Costs Included In Accounts Payable And Accrued Liabilities
WarrantInducementAndEquityIssuanceCostsIncludedInAccountsPayableAndAccruedLiabilities
12000
CY2024Q1 pali Fair Value Of Warrants Issued To Solicitation Agent
FairValueOfWarrantsIssuedToSolicitationAgent
94000
CY2024Q1 pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
0
CY2023Q1 pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
173000
CY2024Q1 pali Cash Receivable For Exercises Of Warrants Included In Prepaid And Other Assets And Other Noncurrent Assets
CashReceivableForExercisesOfWarrantsIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
0
CY2023Q1 pali Cash Receivable For Exercises Of Warrants Included In Prepaid And Other Assets And Other Noncurrent Assets
CashReceivableForExercisesOfWarrantsIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
48000
CY2024Q1 pali Incremental Fair Value Of Modified Or Exchanged Warrants
IncrementalFairValueOfModifiedOrExchangedWarrants
1975000
CY2023Q1 pali Incremental Fair Value Of Modified Or Exchanged Warrants
IncrementalFairValueOfModifiedOrExchangedWarrants
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.045
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125000000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11300000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to accrued research and development expenses and its contingent consideration obligation. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2024Q1 us-gaap Deferred Costs Current
DeferredCostsCurrent
75000
CY2023Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
112000
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market accounts, and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held nor has the Company experienced any losses in these accounts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q1 us-gaap Revenue Recognition Software
RevenueRecognitionSoftware
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Revenue</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company uses the revenue recognition guidance established by ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue From Contracts With Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. The Company currently does not have any collaborative arrangements with counterparties that are also considered customers. For arrangements that include amounts to be paid to the Company upon the achievement of certain development milestones of technology licensed by the Company, the Company recognizes such license revenue using the most likely method. At the end of each reporting period, the Company re-evaluates the probability or achievement of any potential milestones and any related constraints, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment.</span>
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3527000
CY2024Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3527000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2340000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2340000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
768137
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
768137
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
287702
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
287702
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.59
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.59
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.13
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.13
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
348669
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
114105
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
294000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
428000
CY2024Q1 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
153000
CY2023Q4 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
148000
CY2024Q1 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
173000
CY2023Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
138000
CY2024Q1 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
36000
CY2023Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
64000
CY2024Q1 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
75000
CY2023Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
112000
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
6000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
6000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
737000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
896000
CY2024Q1 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
426000
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
478000
CY2024Q1 pali Other Noncurrent Assets
OtherNoncurrentAssets
12000
CY2023Q4 pali Other Noncurrent Assets
OtherNoncurrentAssets
12000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
438000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
490000
CY2024Q1 pali Accrued Accounts Payable
AccruedAccountsPayable
89000
CY2023Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
166000
CY2024Q1 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
10000
CY2023Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
20000
CY2024Q1 pali Accrued Director Stipends
AccruedDirectorStipends
35000
CY2023Q4 pali Accrued Director Stipends
AccruedDirectorStipends
106000
CY2024Q1 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
35000
CY2023Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
131000
CY2024Q1 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
1180000
CY2023Q4 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
98000
CY2024Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
143000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
143000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
178000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
167000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1670000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
831000
CY2024Q1 pali Business Combination Contingent Consideration Liability Noncurrent Determined Fair Value
BusinessCombinationContingentConsiderationLiabilityNoncurrentDeterminedFairValue
204000
CY2023Q4 pali Business Combination Contingent Consideration Liability Noncurrent Determined Fair Value
BusinessCombinationContingentConsiderationLiabilityNoncurrentDeterminedFairValue
204000
CY2024Q1 pali Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
0
CY2024Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
61000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
61000
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
285891
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
272211
CY2023Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
272211
CY2023 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
144.78
CY2023 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y1M13D
CY2024Q1 pali Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
241848
CY2024Q1 pali Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
10.97
CY2024Q1 pali Class Of Warrant Or Right Issued During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife
P4Y10M2D
CY2024Q1 pali Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
228162
CY2024Q1 pali Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
10.97
CY2024Q1 pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod
6
CY2024Q1 pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice
27000
CY2024Q1 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
285891
CY2024Q1 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
107.85
CY2024Q1 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y7M28D
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
131000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
180000
CY2024Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
96000
CY2023Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
175000
CY2024Q1 us-gaap Restructuring Reserve
RestructuringReserve
35000
CY2023Q1 us-gaap Restructuring Reserve
RestructuringReserve
5000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
113000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
93000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
400000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y14D
CY2024Q1 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
1200000
CY2023Q4 pali Accrued Joint Development Expenses
AccruedJointDevelopmentExpenses
100000
CY2024Q1 pali Collaborations And License Agreements Upfront Fee
CollaborationsAndLicenseAgreementsUpfrontFee
1000000
CY2024Q1 us-gaap Royalty Expense
RoyaltyExpense
6750000
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
300000
CY2024Q1 pali Class Of Warrant Or Right Number Of Rights Issued
ClassOfWarrantOrRightNumberOfRightsIssued
1
CY2024Q1 pali Contingent Value Right Pro Rata Net Proceeds From Sale Or Licensing
ContingentValueRightProRataNetProceedsFromSaleOrLicensing
0.80
us-gaap Royalty Expense
RoyaltyExpense
4500000
pali Maximum Aggregate Consideration
MaximumAggregateConsideration
5000000
pali Milestone Payments
MilestonePayments
1500000
pali Closing Period Of Merger Agreement
ClosingPeriodOfMergerAgreement
P48M
pali Proceeds Deposited Into The Cvr Escrow
ProceedsDepositedIntoTheCvrEscrow
0.20
pali Closing Period Of Merger Agreement
ClosingPeriodOfMergerAgreement
P48M
CY2023Q4 pali Collaborations And License Agreements Upfront Fee
CollaborationsAndLicenseAgreementsUpfrontFee
0
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
137000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
59000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
196000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
13000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
183000

Files In Submission

Name View Source Status
0000950170-24-058644-index-headers.html Edgar Link pending
0000950170-24-058644-index.html Edgar Link pending
0000950170-24-058644.txt Edgar Link pending
0000950170-24-058644-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pali-20240331.htm Edgar Link pending
pali-20240331.xsd Edgar Link pending
pali-ex31_1.htm Edgar Link pending
pali-ex31_2.htm Edgar Link pending
pali-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pali-20240331_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending